## Sedat Yılmaz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4641556/publications.pdf

Version: 2024-02-01

73	890	17 h-index	27
papers	citations		g-index
73	73	73	1417
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Amyloidosis and its related factors in Turkish patients with familial Mediterranean fever: a multicentre study. Rheumatology, 2014, 53, 741-745.	1.9	96
2	Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor- $\hat{l}_{\pm}$ Inhibitors: Report from a Large Multicenter Cohort with High Background Prevalence. Journal of Rheumatology, 2016, 43, 524-529.	2.0	67
3	Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still's disease: Data from a large multicenter cohort. Journal of Autoimmunity, 2016, 69, 59-63.	6.5	62
4	Nationwide Experience With Offâ€Label Use of Interleukinâ€1 Targeting Treatment in Familial Mediterranean Fever Patients. Arthritis Care and Research, 2018, 70, 1090-1094.	3.4	48
5	The factors considered as trigger for the attacks in patients with familial Mediterranean fever. Rheumatology International, 2013, 33, 893-897.	3.0	39
6	Tocilizumab in the treatment of patients with AA amyloidosis secondary to familial Mediterranean fever. Rheumatology, 2015, 54, 564-565.	1.9	39
7	Diagnostic dilemma of paraneoplastic arthritis: case series. International Journal of Rheumatic Diseases, 2014, 17, 640-645.	1.9	36
8	Living with scleroderma: patients' perspectives, a phenomenological study. Rheumatology International, 2012, 32, 3573-3579.	3.0	27
9	Comparison of early versus late onset familial Mediterranean fever. International Journal of Rheumatic Diseases, 2018, 21, 880-884.	1.9	25
10	Treatment of idiopathic granulomatous mastitis and factors related with disease recurrence. Turkish Journal of Medical Sciences, 2020, 50, 1380-1386.	0.9	24
11	The distribution of MEFV mutations in Turkish FMF patients: multicenter study representing results of Anatolia. Turkish Journal of Medical Sciences, 2019, 49, 472-477.	0.9	23
12	Patient-driven assessment of disease activity in Behçet's syndrome: cross-cultural adaptation, reliability and validity of the Turkish version of the Behçet's Syndrome Activity Score. Clinical and Experimental Rheumatology, 2013, 31, 77-83.	0.8	23
13	Value of DWI in visual assessment of activity of sacroiliitis in longstanding ankylosing spondylitis patients. Skeletal Radiology, 2013, 42, 289-293.	2.0	20
14	Cross-Cultural Adaptation, Reliability, and Validity of the Turkish Version of the Compliance Questionnaire on Rheumatology in Patients With Behçet's Disease. Journal of Transcultural Nursing, 2016, 27, 480-486.	1.3	20
15	A polymorphism in ERAP1 is associated with susceptibility to ankylosing spondylitis in a Turkish population. Rheumatology International, 2013, 33, 2851-2858.	3.0	19
16	A patient-reported outcome measures-based composite index (RAPID3) for the assessment of disease activity in ankylosing spondylitis. Rheumatology International, 2015, 35, 1575-1580.	3.0	19
17	Quantitative Analysis of Optical Coherence Tomography Angiography Features in Patients with Nonocular Behcet's Disease. Current Eye Research, 2019, 44, 212-218.	1.5	19
18	Relationship of ultrasonographic findings with synovial angiogenesis modulators in different forms of knee arthritides. Rheumatology International, 2013, 33, 879-885.	3.0	18

#	Article	IF	Citations
19	Sarcopenia in rheumatoid arthritis: Is it a common manifestation?. International Journal of Rheumatic Diseases, 2020, 23, 1685-1691.	1.9	15
20	Reliability and validity of the Turkish translation of the beliefs about medicines questionnaire (BMQ-T) in patients with BehA§et's disease. Clinical and Experimental Rheumatology, 2016, 34, S46-S51.	0.8	15
21	Investigation of the veins in patients with Behçet's disease with no known vascular event by Doppler ultrasonography. Rheumatology International, 2012, 32, 303-306.	3.0	12
22	Apparent diffusion coefficients of sacroiliitis in patients with established ankylosing spondylitis. Clinical Imaging, 2013, 37, 734-739.	1.5	12
23	Familial Mediterranean fever gene mutations as a risk factor for early coronary artery disease. International Journal of Rheumatic Diseases, 2017, 20, 2113-2117.	1.9	12
24	Long-term efficacy and safety of Anakinra in a patient with liver transplant due to Adult onset Still's Disease. Modern Rheumatology, 2014, 24, 1030-1031.	1.8	10
25	Retro-orbital granuloma associated with granulomatosis with polyangiitis: a series of nine cases. Rheumatology International, 2015, 35, 1083-1092.	3.0	10
26	A case of exogenous ochronosis associated with hydroxychloroquine. European Journal of Rheumatology, 2018, 5, 206-208.	0.6	10
27	Exon 2: Is it the good police in familial mediterranean fever?. European Journal of Rheumatology, 2019, 6, 33-36.	0.6	10
28	Ulnar artery aneurysm in a patient with Behçet's disease. Rheumatology International, 2010, 30, 383-385.	3.0	9
29	Varicocele and Epididymitis in Behçet Disease. Journal of Ultrasound in Medicine, 2011, 30, 909-913.	1.7	9
30	Non-adherence to colchicine treatment is a common misevaluation in familial Mediterranean fever. Turkish Journal of Medical Sciences, 2021, 51, 2357-2363.	0.9	9
31	Criteria sets for primary Sjogren's syndrome are not adequate for those presenting with extraglandular organ involvements as their dominant clinical features. Rheumatology International, 2017, 37, 675-684.	3.0	8
32	The assessment of tocilizumab therapy on recurrent attacks of patients with familial Mediterranean fever: A retrospective study of 15 patients. Modern Rheumatology, 2021, 31, 223-225.	1.8	8
33	Investigation of the arterial stiffness and associated factors in patients with familial Mediterranean fever. Anatolian Journal of Cardiology, 2017, 17, 132-138.	0.9	8
34	The expression of transmembrane and soluble CXCL16 and the relation with interferon-alpha secretion in patients with BehĀset's disease. Clinical and Experimental Rheumatology, 2013, 31, 84-7.	0.8	8
35	Systemic involvements and preferred treatments in a large cohort of Behçet's disease. Rheumatology International, 2013, 33, 3025-3030.	3.0	7
36	Thoughts and perceptions of ankylosing spondylitis patients with regard to TNF inhibitors. Rheumatology International, 2014, 34, 979-986.	3.0	7

#	Article	IF	CITATIONS
37	Methodology of a new inflammatory arthritis registry: TReasure. Turkish Journal of Medical Sciences, 2018, 48, 856-861.	0.9	7
38	Predictive factors for workâ€day loss in Behçet's syndrome: A multiâ€center study. International Journal of Rheumatic Diseases, 2020, 23, 240-246.	1.9	7
39	Recurrence of proteinuria after cessation of tocilizumab in patients with AA amyloidosis secondary to FMF. European Journal of Rheumatology, 2018, 5, 278-280.	0.6	7
40	Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab. Therapeutics and Clinical Risk Management, 2013, 9, 403.	2.0	6
41	Muscle involvement in two Behçet cases: magnetic resonance imaging and histology findings. Japanese Journal of Radiology, 2014, 32, 233-237.	2.4	6
42	Assessment of the effects of loneliness, perceived social support, and depression on medication adherence in patients with ankylosing spondylitis. Perspectives in Psychiatric Care, 2021, 57, 517-523.	1.9	6
43	Use of complementary and alternative medicine in patients with ankylosing spondylitis. European Journal of Rheumatology, 2021, 8, 20-26.	0.6	6
44	Coping strategies for activities of daily living in women whose hands affected by systemic sclerosis. Journal of Clinical Nursing, 2014, 23, 1630-1638.	3.0	5
45	Moderation analysis exploring associations between age and mucocutaneous activity in Behçet's syndrome: A multicenter study from Turkey. Journal of Dermatology, 2020, 47, 1403-1410.	1.2	4
46	The presence of <i>MEFV</i> gene mutations in patients with primary osteoarthritis who require surgery. Korean Journal of Internal Medicine, 2013, 28, 594.	1.7	4
47	Reliability and Validity of the Turkish Translation of the Beliefs about Medicines Questionnaire (BMQ-T) in Patients with Behçet's Disease. Turkish Thoracic Journal, 2018, 19, 231-232.	0.6	4
48	Comparison of the efficacy of written information vs. verbal plus written information in rheumatic patients who receive colchicine treatment. Gulhane Medical Journal, 2013, 55, 94.	0.2	3
49	Successful treatment of PR3â€ANCA positive vasculitis with pancreatitis as the first manifestation with rituximab. International Journal of Rheumatic Diseases, 2017, 20, 2209-2210.	1.9	3
50	Anterior spinal cord syndrome in a patient with Beh $\tilde{A}$ §et's disease. Bulletin of the NYU Hospital for Joint Diseases, 2012, 70, 120-3.	0.7	3
51	A case of leishmaniasis with a lupus-like presentation. Seminars in Arthritis and Rheumatism, 2015, 45, e3-e4.	3.4	2
52	Onycho-Pachydermatit with extensive bone marrow edema predominant in the metacarpals: a "forme fruste―of POPP?. Rheumatology International, 2012, 32, 1449-1452.	3.0	1
53	Evolução clÃnica da doença de Behçet em paciente com atraso do diagnóstico e seguimento radiológico dos trombos com angiotomografia computadorizada: seguimento por 5 anos durante tratamento imunossupressor. Revista Brasileira De Reumatologia, 2017, 57, 264-269.	0.8	1
54	Physicians' Biological Drug Preference in Patients With Rheumatoid Arthritis and Spondyloarthritis With a History of Malignancy. Journal of Clinical Rheumatology, 2021, Publish Ahead of Print, .	0.9	1

#	Article	IF	CITATIONS
55	Comparison of vitamin D levels between patients with pterygium and healthy subjects. International Ophthalmology, 2021, 41, 3057-3064.	1.4	1
56	In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?. Rheumatology International, 2021, 41, 1915-1924.	3.0	1
57	reality of living with familial mediterranean fever identity: a phenomenological study. Gulhane Medical Journal, 2019, 61, 33.	0.2	1
58	Autonomic functions in acrocyanosis assessed by heart rate variability. European Journal of Rheumatology, 2014, 1, 18-20.	0.6	1
59	MEFV gene mutation frequency and distribution of mutations in FMF patients: Analysis of a large group of patients from a single center. Gulhane Medical Journal, 2017, , 1.	0.2	1
60	Investigation of joint hypermobility in individuals with hyperbilirubinemia. European Journal of Rheumatology, 2017, 4, 36-39.	0.6	1
61	A rare cause of reactive arthritis etiology: bacillus calmette-guerin immunotherapy. Gulhane Medical Journal, 2019, 61, 28.	0.2	1
62	Comment on †Treatment of idiopathic granulomatous mastitis and factors related with disease recurrence'. Turkish Journal of Medical Sciences, 2020, 50, 2073-2074.	0.9	1
63	The importance of R202Q polymorphism in clinical expression of Familial Mediterranean Fever. Gulhane Medical Journal, 2020, 62, 157-162.	0.2	1
64	Complementary and alternative medicine usage in patients with Familial Mediterranean Fever. Gulhane Medical Journal, 2020, 62, 239-244.	0.2	1
65	Biological treatment in resistant adult-onset Still's disease: A single-center, retrospective cohort study. Archives of Rheumatology, 2022, 37, 11-18.	0.9	1
66	THU0410â€UVEITIS RELATED FACTORS IN PATIENTS WITH SPONDYLOARTHRITIS. , 2019, , .		0
67	A case of dermatomyositis that cause respiratuar muscle weakness and interstitial pneumonia. Gulhane Medical Journal, 2015, 57, 190.	0.2	0
68	Immune globulin g4 associated disease: immunosuppressive treatment should be considered. Gulhane Medical Journal, 2018, 60, 30.	0.2	0
69	Rare rheumatologic disease of elderly patients: remitting seronegative symmetrical synovitis with pitting edema. Gulhane Medical Journal, 2018, 60, 153.	0.2	0
70	A case of axial spondyloarthritis with paget"s disease: a rare coexistence. Gulhane Medical Journal, 2019, 61, 88.	0.2	0
71	The frequency and reasons of non-attendance of patients to their appointments at a rheumatology outpatient clinic. Ulusal Romatoloji Dergisi, 2020, 12, 51-56.	0.0	0
72	Biological treatment in resistant adult-onset Still's disease: A single-center, retrospective cohort study. Archives of Rheumatology, 0, , .	0.9	0

#	Article	IF	CITATIONS
73	The assessment of rheumatologic immune-related adverse events with immune checkpoint inhibitors. Gulhane Medical Journal, 2022, 64, 103-109.	0.2	O